
News|Articles|May 1, 2002
No advantage to omapatrilat over enalapril in heart failure . . .
The investigational vasopeptidase inhibitor omapatrilat is as effective as enalapril in preventing major adverse cardiac outcomes in patients with moderate to severe heart failure, but failed to show superiority, said Milton Packer, MD.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Will the end of enhanced ACA subsidies mean the beginning of a health insurance crisis?
2
Pharmacy leaders in ASHP survey worry about 340B program changes
3
FDA approves first postmenopausal libido treatment, Addyi
4
Johns Hopkins experts warn of potentially severe flu season, measles elimination status faces risk
5


















































